Tianjin Chase Sun Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tianjin Chase Sun Pharmaceutical Company Limited with three other
companies in this sector in China:
Zhangzhou Pientzehuang Pharmaceutical Ltd
sales of 3.71 billion Chinese Renmimbi [US$587.92 million]
of which 51%
was Pharmaceutical Business),
Jiangsu Kanion Pharmaceutical Co., Ltd.
(3.27 billion Chinese Renmimbi [US$518.38 million]
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
(3.18 billion Chinese Renmimbi [US$503.76 million]
During the year ended December of 2017, sales at
Tianjin Chase Sun Pharmaceutical Company Limited were 3.37 billion Chinese Renmimbi (US$534.10 million).
decrease of 12.7%
versus 2016, when the company's sales were 3.87 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 27.8% decline
in Finished Medicine, from 1.29 billion Chinese Renmimbi to 931.33 million Chinese Renmimbi.
There were also decreases in sales in
Granules (down 6.6% to 1.75 billion Chinese Renmimbi)
Medical Devices (down 18.6% to 239.43 million Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Excipients and Api (up 8.3% to 375.70 million Chinese Renmimbi)
Other Main Operation (up 28.3% to 74.72 million Chinese Renmimbi)